Greenstone Biosciences on a Quest for Duchenne Muscular Dystrophy Therapeutics with New Funding from CIRM

2023-02-02

投融资

Palo Alto, CA, February 1, 2023 - Recently, the California Institute of Regenerative Medicine (CIRM) awarded Greenstone Bio $675,000 to find novel treatments for Duchenne Muscular Dystrophy (DMD), a fatal genetic disease with no current cure. Cardiomyopathies are highly prevalent and the leading cause of death in this disease. Most DMD patients develop cardiomyopathy (symptoms include palpitation, shortness of breath, etc.) between the ages of 10-15 years, followed by cardiac-related death in their 20’s. There are no specific treatments available for DMD-associated cardiomyopathy. Greenstone scientists will utilize iPSCs derived from numerous DMD patients that they have already generated to establish a “clinical trial in a dish” approach for DMD preclinical testing and drug discovery. “Our iPSC-based model to determine DMD-specific drug response in a dish is a powerful approach to ensure safety and efficacy quickly in a cost-effective manner”, says Dr. Joseph Wu, Greenstone Co-Founder and Director of the Stanford Cardiovascular Institute and the Simon H. Stertzer, MD, Professor of Medicine & Radiology at Stanford University ( ). Lip-Bu Tan of Walden Catalyst Venture, investor of Greenstone Biosciences, adds, "This award from CIRM is a validation of the engine that Greenstone Bio has built to advance translational medicine from bench to bedside." Greenstone Biosciences, located in Palo Alto, CA, is a biotechnology company utilizing the latest advancements in clinical genomics, computational biology, and patient-specific iPSCs to understand pharmacogenomics and speed up drug discovery. Greenstone Bio has extensive knowledge and expertise in generating patient-derived iPSCs and currently holds the largest human induced pluripotent stem cell (iPSC) biobank. The biobank comprises patient-derived iPSCs spanning numerous diseases from ethnically diverse individuals. Greenstone Bio offers iPSC lines to academic collaborators at no cost, with several top institutions partnering to accelerate personalized medicine. For more information please visit: Contact: Jade Chao, JD Chief Operating Officer Greenstone Biosciences, Inc. jadechao@greenstonebio.com

机构